The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015

Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, et al. (2017)
JAMA ONCOLOGY 3(12): 1683-1691.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Akinyemiju, Tomi; Abera, Semaw; Ahmed, Muktar; Alam, Noore; Alemayohu, Mulubirhan Assefa; Allen, Christine; Al-Raddadi, Rajaa; Alvis-Guzman, Nelson; Amoako, Yaw; Artaman, Al; Ayele, Tadesse Awoke; Barac, Aleksandra
Alle
Abstract / Bemerkung
IMPORTANCE Liver cancer is among the leading causes of cancer deaths globally. The most common causes for liver cancer include hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol use. OBJECTIVE To report results of the Global Burden of Disease (GBD) 2015 study on primary liver cancer incidence, mortality, and disability-adjusted life-years (DALYs) for 195 countries or territories from 1990 to 2015, and present global, regional, and national estimates on the burden of liver cancer attributable to HBV, HCV, alcohol, and an " other" group that encompasses residual causes. DESIGN, SETTINGS, AND PARTICIPANTS Mortalitywas estimated using vital registration and cancer registry data in an ensemble modeling approach. Single-cause mortality estimates were adjusted for all-cause mortality. Incidence was derived from mortality estimates and the mortality-to-incidence ratio. Through a systematic literature review, data on the proportions of liver cancer due to HBV, HCV, alcohol, and other causes were identified. Years of life lost were calculated by multiplying each death by a standard life expectancy. Prevalence was estimated using mortality-to-incidence ratio as surrogate for survival. Total prevalence was divided into 4 sequelae that were multiplied by disability weights to derive years lived with disability (YLDs). DALYs were the sum of years of life lost and YLDs. MAIN OUTCOMES AND MEASURES Liver cancer mortality, incidence, YLDs, years of life lost, DALYs by etiology, age, sex, country, and year. RESULTS There were 854 000 incident cases of liver cancer and 810 000 deaths globally in 2015, contributing to 20 578 000 DALYs. Cases of incident liver cancer increased by 75% between 1990 and 2015, of which 47% can be explained by changing population age structures, 35% by population growth, and -8% to changing age-specific incidence rates. The male-to-female ratio for age-standardized liver cancer mortality was 2.8. Globally, HBV accounted for 265 000 liver cancer deaths (33%), alcohol for 245 000 (30%), HCV for 167 000 (21%), and other causes for 133 000 (16%) deaths, with substantial variation between countries in the underlying etiologies. CONCLUSIONS AND RELEVANCE Liver cancer is among the leading causes of cancer deaths in many countries. Causes of liver cancer differ widely among populations. Our results show that most cases of liver cancer can be prevented through vaccination, antiviral treatment, safe blood transfusion and injection practices, as well as interventions to reduce excessive alcohol use. In line with the Sustainable Development Goals, the identification and elimination of risk factors for liver cancer will be required to achieve a sustained reduction in liver cancer burden. The GBD study can be used to guide these prevention efforts.
Erscheinungsjahr
2017
Zeitschriftentitel
JAMA ONCOLOGY
Band
3
Ausgabe
12
Seite(n)
1683-1691
ISSN
2374-2437
eISSN
2374-2445
Page URI
https://pub.uni-bielefeld.de/record/2916413

Zitieren

Akinyemiju T, Abera S, Ahmed M, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. JAMA ONCOLOGY. 2017;3(12):1683-1691.
Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., et al. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. JAMA ONCOLOGY, 3(12), 1683-1691. doi:10.1001/jamaoncol.2017.3055
Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., Artaman, A., et al. (2017). The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. JAMA ONCOLOGY 3, 1683-1691.
Akinyemiju, T., et al., 2017. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. JAMA ONCOLOGY, 3(12), p 1683-1691.
T. Akinyemiju, et al., “The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015”, JAMA ONCOLOGY, vol. 3, 2017, pp. 1683-1691.
Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M.A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., Artaman, A., Ayele, T.A., Barac, A., Bensenor, I., Berhane, A., Bhutta, Z., Castillo-Rivas, J., Chitheer, A., Choi, J.-Y., Cowie, B., Dandona, L., Dandona, R., Dey, S., Dicker, D., Phuc, H., Ekwueme, D.U., Zaki, M.E.S., Fischer, F., Furst, T., Hancock, J., Hay, S.I., Hotez, P., Jee, S.H., Kasaeian, A., Khader, Y., Khang, Y.-H., Kumar, G.A., Kutz, M., Larson, H., Lopez, A., Lunevicius, R., Malekzadeh, R., McAlinden, C., Meier, T., Mendoza, W., Mokdad, A., Moradi-Lakeh, M., Nagel, G., Nguyen, Q., Nguyen, G., Ogbo, F., Patton, G., Pereira, D.M., Pourmalek, F., Qorbani, M., Radfar, A., Roshandel, G., Salomon, J.A., Sanabria, J., Sartorius, B., Satpathy, M., Sawhney, M., Sepanlou, S., Shackelford, K., Shore, H., Sun, J., Mengistu, D.T., Topor-Madry, R., Tran, B., Ukwaja, K.N., Vlassov, V., Vollset, S.E., Vos, T., Wakayo, T., Weiderpass, E., Werdecker, A., Yonemoto, N., Younis, M., Yu, C., Zaidi, Z., Zhu, L., Murray, C.J.L., Naghavi, M., Fitzmaurice, C.: The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. JAMA ONCOLOGY. 3, 1683-1691 (2017).
Akinyemiju, Tomi, Abera, Semaw, Ahmed, Muktar, Alam, Noore, Alemayohu, Mulubirhan Assefa, Allen, Christine, Al-Raddadi, Rajaa, Alvis-Guzman, Nelson, Amoako, Yaw, Artaman, Al, Ayele, Tadesse Awoke, Barac, Aleksandra, Bensenor, Isabela, Berhane, Adugnaw, Bhutta, Zulfiqar, Castillo-Rivas, Jacqueline, Chitheer, Abdulaal, Choi, Jee-Young, Cowie, Benjamin, Dandona, Lalit, Dandona, Rakhi, Dey, Subhojit, Dicker, Daniel, Phuc, Huyen, Ekwueme, Donatus U., Zaki, Maysaa El Sayed, Fischer, Florian, Furst, Thomas, Hancock, Jamie, Hay, Simon I., Hotez, Peter, Jee, Sun Ha, Kasaeian, Amir, Khader, Yousef, Khang, Young-Ho, Kumar, G. Anil, Kutz, Michael, Larson, Heidi, Lopez, Alan, Lunevicius, Raimundas, Malekzadeh, Reza, McAlinden, Colm, Meier, Toni, Mendoza, Walter, Mokdad, Ali, Moradi-Lakeh, Maziar, Nagel, Gabriele, Nguyen, Quyen, Nguyen, Grant, Ogbo, Felix, Patton, George, Pereira, David M., Pourmalek, Farshad, Qorbani, Mostafa, Radfar, Amir, Roshandel, Gholamreza, Salomon, Joshua A., Sanabria, Juan, Sartorius, Benn, Satpathy, Maheswar, Sawhney, Monika, Sepanlou, Sadaf, Shackelford, Katya, Shore, Hirbo, Sun, Jiandong, Mengistu, Desalegn Tadese, Topor-Madry, Roman, Tran, Bach, Ukwaja, Kingsley Nnanna, Vlassov, Vasiliy, Vollset, Stein Emil, Vos, Theo, Wakayo, Tolassa, Weiderpass, Elisabete, Werdecker, Andrea, Yonemoto, Naohiro, Younis, Mustafa, Yu, Chuanhua, Zaidi, Zoubida, Zhu, Liguo, Murray, Christopher J. L., Naghavi, Mohsen, and Fitzmaurice, Christina. “The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015”. JAMA ONCOLOGY 3.12 (2017): 1683-1691.

76 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX., Clin Cancer Res 25(1), 2019
PMID: 30190369
Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood.
McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC., Gastroenterology 156(2), 2019
PMID: 30268787
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.
Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F, Thibault V, Fartoux L, Lucidarme O, Eyraud D, Scatton O, Savier E, Valantin MA, Ngo A, Drane F, Rosmorduc O, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, HECAM-FibroFrance Group., Aliment Pharmacol Ther 49(3), 2019
PMID: 30569507
High prevalence of nonalcoholic steatohepatitis and abnormal liver stiffness in a young and obese Mexican population.
Sepulveda-Villegas M, Roman S, Rivera-Iñiguez I, Ojeda-Granados C, Gonzalez-Aldaco K, Torres-Reyes LA, Jose-Abrego A, Panduro A., PLoS One 14(1), 2019
PMID: 30608932
ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma.
Zhou Z, Jiang H, Tu K, Yu W, Zhang J, Hu Z, Zhang H, Hao D, Huang P, Wang J, Wang A, Xiao Z, He C., J Exp Clin Cancer Res 38(1), 2019
PMID: 30646949
Cytostatic and Anti-tumor Potential of Ajwa Date Pulp against Human Hepatocellular Carcinoma HepG2 Cells.
Siddiqui S, Ahmad R, Khan MA, Upadhyay S, Husain I, Srivastava AN., Sci Rep 9(1), 2019
PMID: 30664656
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma.
Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P., Front Oncol 9(), 2019
PMID: 30719425
Downregulation of PDK4 Increases Lipogenesis and Associates with Poor Prognosis in Hepatocellular Carcinoma.
Yang C, Wang S, Ruan H, Li B, Cheng Z, He J, Zuo Q, Yu C, Wang H, Lv Y, Gu D, Jin G, Yao M, Qin W, Jin H., J Cancer 10(4), 2019
PMID: 30854098
Liver Cancer in Guatemala: An Analysis of Mortality and Incidence Trends From 2012 to 2016.
Kihn-Alarcón AJ, Toledo-Ponce MF, Velarde A, Xu X., J Glob Oncol 5(), 2019
PMID: 30835603
Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances.
Navin PJ, Venkatesh SK., J Clin Transl Hepatol 7(1), 2019
PMID: 30944823
Treatment strategies for locally advanced hepatocellular carcinoma.
Fernandes ESM, Rodrigues PD, Álvares-da-Silva MR, Scaffaro LA, Farenzena M, Teixeira UF, Waechter FL., Transl Gastroenterol Hepatol 4(), 2019
PMID: 30976715
Growing burden of alcoholic liver disease in China: A review.
Wang WJ, Xiao P, Xu HQ, Niu JQ, Gao YH., World J Gastroenterol 25(12), 2019
PMID: 30948908
Treatment selection of recurrent hepatocellular carcinoma with microvascular invasion at the initial hepatectomy.
Xiao H, Chen ZB, Jin HL, Li B, Xu LX, Guo Y, Chen SL, Li HP, Peng ZW, Shen JX., Am J Transl Res 11(3), 2019
PMID: 30972210
Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma.
Huang KW, Jayant K, Lee PH, Yang PC, Hsiao CY, Habib N, Sodergren MH., J Clin Med 8(3), 2019
PMID: 30893948
Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma.
Scheiner B, Ulbrich G, Mandorfer M, Reiberger T, Müller C, Waneck F, Trauner M, Kölblinger C, Ferlitsch A, Sieghart W, Peck-Radosavljevic M, Pinter M., United European Gastroenterol J 7(6), 2019
PMID: 31316789
Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach.
Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G., Int J Mol Sci 20(6), 2019
PMID: 30909504
miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.
Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T., Onco Targets Ther 12(), 2019
PMID: 30962696
Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: a national cohort study.
Sinn DH, Kang D, Kang M, Paik SW, Guallar E, Cho J, Gwak GY., BMC Cancer 19(1), 2019
PMID: 30922251
Knowledge, attitudes and practices of hepatitis B prevention and immunization of pregnant women and mothers in northern Vietnam.
Hang Pham TT, Le TX, Nguyen DT, Luu CM, Truong BD, Tran PD, Toy M, So S., PLoS One 14(4), 2019
PMID: 30969972
Impact of Hepatitis Virus on the Feasibility and Efficacy of Anticancer Agents in Patients With Hepatocellular Carcinoma in Phase I Clinical Trials.
Koyama T, Kondo S, Shimizu T, Fujiwara Y, Morizane C, Sakamoto Y, Okusaka T, Yamamoto N., Front Oncol 9(), 2019
PMID: 31058094
Role of US LI-RADS in the LI-RADS Algorithm.
Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A., Radiographics 39(3), 2019
PMID: 31059393
Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma.
Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD., World J Gastroenterol 25(20), 2019
PMID: 31171895
Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study.
Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML., BMJ Open 9(5), 2019
PMID: 31061041
Macro Histone Variants: Emerging Rheostats of Gastrointestinal Cancers.
Giallongo S, Lo Re O, Vinciguerra M., Cancers (Basel) 11(5), 2019
PMID: 31096699
Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma.
Chen CP., J Clin Transl Hepatol 7(2), 2019
PMID: 31293919
Immunotherapy for hepatocellular carcinoma: Current and future.
Johnston MP, Khakoo SI., World J Gastroenterol 25(24), 2019
PMID: 31293335
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.
Raoul JL, Frenel JS, Raimbourg J, Gilabert M., Hepat Oncol 6(1), 2019
PMID: 31244990
Overexpression of miR-450 affects the biological behavior of HepG2 cells by targeting DNMT3a.
Wang Y, Wang L, Yu X, Duan J., Onco Targets Ther 12(), 2019
PMID: 31303764
The diagnostic and prognostic role of RhoA in hepatocellular carcinoma.
Bai Y, Xie F, Miao F, Long J, Huang S, Huang H, Lin J, Wang D, Yang X, Bian J, Mao J, Wang X, Mao Y, Sang X, Zhao H., Aging (Albany NY) 11(14), 2019
PMID: 31339860
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM., World J Gastroenterol 25(28), 2019
PMID: 31391767
The risk of liver cancer in autoimmune liver diseases.
Lleo A, de Boer YS, Liberal R, Colombo M., Ther Adv Med Oncol 11(), 2019
PMID: 31320937
The Metabolism of Renal Cell Carcinomas and Liver Cancer.
Nguyen T, Le A., Adv Exp Med Biol 1063(), 2018
PMID: 29946779
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies.
Schaub SK, Hartvigson PE, Lock MI, Høyer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S., Technol Cancer Res Treat 17(), 2018
PMID: 30068240
How to improve access to therapy in hepatitis B patients.
Subic M, Zoulim F., Liver Int 38 Suppl 1(), 2018
PMID: 29427482
Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.
Pyenson BS, Dieguez G, Ferro C, Mavinkurve M, Gonzalez YS., Am Health Drug Benefits 11(1), 2018
PMID: 29692878
Liver Transplantation for Alcoholic Liver Disease and Hepatocellular Carcinoma.
Burra P, Zanetto A, Germani G., Cancers (Basel) 10(2), 2018
PMID: 29425151
Hepatitis B At-Birth Dose Vaccine: An Urgent Call for Implementation in Ghana.
Awuku YA, Yeboah-Afihene M., Vaccines (Basel) 6(1), 2018
PMID: 29534503
Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y., PLoS One 13(4), 2018
PMID: 29689073
Ambient PM2.5 air pollution exposure and hepatocellular carcinoma incidence in the United States.
VoPham T, Bertrand KA, Tamimi RM, Laden F, Hart JE., Cancer Causes Control 29(6), 2018
PMID: 29696510
Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4+ T cell apoptosis promoting HCC development.
Brown ZJ, Fu Q, Ma C, Kruhlak M, Zhang H, Luo J, Heinrich B, Yu SJ, Zhang Q, Wilson A, Shi ZD, Swenson R, Greten TF., Cell Death Dis 9(6), 2018
PMID: 29795111
Self-assembled dual fluorescence nanoparticles for CD44-targeted delivery of anti-miR-27a in liver cancer theranostics.
Zheng X, Zhang F, Zhao Y, Zhang J, Dawulieti J, Pan Y, Cui L, Sun M, Shao D, Li M, He K, Zhang M, Li J, Chen L., Theranostics 8(14), 2018
PMID: 30083261
Oral chemotherapy for the treatment of hepatocellular carcinoma.
Yamamoto S, Kondo S., Expert Opin Pharmacother 19(9), 2018
PMID: 29913090
Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma.
Aryal B, Yamakuchi M, Shimizu T, Kadono J, Furoi A, Gejima K, Komokata T, Hashiguchi T, Imoto Y., Can J Gastroenterol Hepatol 2018(), 2018
PMID: 30050894
Precision oncology in liver cancer.
Sullivan KM, Kenerson HL, Pillarisetty VG, Riehle KJ, Yeung RS., Ann Transl Med 6(14), 2018
PMID: 30105235
How to select the appropriate "neoadjuvant therapy" for hepatocellular carcinoma.
Liu K, McCaughan GW., Expert Opin Pharmacother 19(11), 2018
PMID: 30011239
Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma.
Kotha S, Neong S, Patel K., Expert Rev Mol Diagn 18(8), 2018
PMID: 30019978
Role of hepatoma-derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma.
Min X, Wen J, Zhao L, Wang K, Li Q, Huang G, Liu J, Zhao X., Mol Oncol 12(9), 2018
PMID: 30004626
Liver cancer mortality trends in South Africa: 1999-2015.
Mak D, Sengayi M, Chen WC, Babb de Villiers C, Singh E, Kramvis A., BMC Cancer 18(1), 2018
PMID: 30086727
Alcoholic liver disease.
Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, Mathurin P, Mueller S, Szabo G, Tsukamoto H., Nat Rev Dis Primers 4(1), 2018
PMID: 30115921
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.
Brown ZJ, Heinrich B, Greten TF., Nat Rev Gastroenterol Hepatol 15(9), 2018
PMID: 29904153
Biomarkers for hepatocellular carcinoma: What's new on the horizon?
Ocker M., World J Gastroenterol 24(35), 2018
PMID: 30254402
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy.
Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I., World J Hepatol 10(9), 2018
PMID: 30310535
Systemic treatment for hepatocellular carcinoma.
Aggarwal M, Arain A, Jin Z., Chronic Dis Transl Med 4(3), 2018
PMID: 30276361
Hepatitis B virus promotes β-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
von Olshausen G, Quasdorff M, Bester R, Arzberger S, Ko C, van de Klundert M, Zhang K, Odenthal M, Ringelhan M, Niessen CM, Protzer U., Oncotarget 9(74), 2018
PMID: 30338037
Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population.
Kim NJ, Magee C, Cummings C, Park H, Khalili M., Hepatol Commun 2(10), 2018
PMID: 30288480
Tuberculosis disease burden and attributable risk factors in Nigeria, 1990-2016.
Ogbo FA, Ogeleka P, Okoro A, Olusanya BO, Olusanya J, Ifegwu IK, Awosemo AO, Eastwood J, Page A., Trop Med Health 46(), 2018
PMID: 30262990
Epidemiology of hepatitis B, C and D in Malawi: systematic review.
Stockdale AJ, Mitambo C, Everett D, Geretti AM, Gordon MA., BMC Infect Dis 18(1), 2018
PMID: 30314448
The burden of depressive disorders in South Asia, 1990-2016: findings from the global burden of disease study.
Ogbo FA, Mathsyaraja S, Koti RK, Perz J, Page A., BMC Psychiatry 18(1), 2018
PMID: 30326863
Regorafenib: a promising treatment for hepatocellular carcinoma.
Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A., Expert Opin Pharmacother 19(17), 2018
PMID: 30345837
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castañeda-Orjuela CA, Catalá-López F, Choi JJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, das Neves J, Dey S, Dharmaratne SD, Doku DT, Driscoll TR, Dubey M, Ebrahimi H, Edessa D, El-Khatib Z, Endries AY, Fischer F, Force LM, Foreman KJ, Gebrehiwot SW, Gopalani SV, Grosso G, Gupta R, Gyawali B, Hamadeh RR, Hamidi S, Harvey J, Hassen HY, Hay RJ, Hay SI, Heibati B, Hiluf MK, Horita N, Hosgood HD, Ilesanmi OS, Innos K, Islami F, Jakovljevic MB, Johnson SC, Jonas JB, Kasaeian A, Kassa TD, Khader YS, Khan EA, Khan G, Khang YH, Khosravi MH, Khubchandani J, Kopec JA, Kumar GA, Kutz M, Lad DP, Lafranconi A, Lan Q, Legesse Y, Leigh J, Linn S, Lunevicius R, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, McMahon BJ, Meier T, Melaku YA, Melku M, Memiah P, Mendoza W, Meretoja TJ, Mezgebe HB, Miller TR, Mohammed S, Mokdad AH, Moosazadeh M, Moraga P, Mousavi SM, Nangia V, Nguyen CT, Nong VM, Ogbo FA, Olagunju AT, Pa M, Park EK, Patel T, Pereira DM, Pishgar F, Postma MJ, Pourmalek F, Qorbani M, Rafay A, Rawaf S, Rawaf DL, Roshandel G, Safiri S, Salimzadeh H, Sanabria JR, Santric Milicevic MM, Sartorius B, Satpathy M, Sepanlou SG, Shackelford KA, Shaikh MA, Sharif-Alhoseini M, She J, Shin MJ, Shiue I, Shrime MG, Sinke AH, Sisay M, Sligar A, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tessema GA, Topor-Madry R, Tran TT, Tran BX, Ukwaja KN, Vlassov VV, Vollset SE, Weiderpass E, Williams HC, Yimer NB, Yonemoto N, Younis MZ, Murray CJL, Naghavi M., JAMA Oncol 4(11), 2018
PMID: 29860482
[Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors].
Stippel DL, Wahba R, Bruns CJ, Bunck A, Baues C, Persigehl T., Chirurg 89(11), 2018
PMID: 30030546
Liver cancer incidence and mortality in China: Temporal trends and projections to 2030.
Zheng R, Qu C, Zhang S, Zeng H, Sun K, Gu X, Xia C, Yang Z, Li H, Wei W, Chen W, He J., Chin J Cancer Res 30(6), 2018
PMID: 30700925
Prognostic Significance of Tumor Location for Liver Cancer Radiotherapy.
Dar AR, McKillop I, Vickress J, Lock M, Yartsev S., Cureus 10(12), 2018
PMID: 30788203
Clinical Implication and the Hereditary Factors of NM23 in Hepatocellular Carcinoma Based on Bioinformatics Analysis and Genome-Wide Association Study.
Yang C, Han C, Wang X, Liao X, Liu X, Qin W, Yu L, Zhu G, Su H, Lu S, Chen Z, Yu T, Liu Z, Huang K, Liu Z, Liang Y, Huang J, Peng T., J Oncol 2018(), 2018
PMID: 30662464
Impact of direct-acting antiviral agents on the risk for hepatocellular carcinoma.
Adhoute X, Castellani P, Bourlière M., Transl Gastroenterol Hepatol 2(), 2017
PMID: 29354767

45 References

Daten bereitgestellt von Europe PubMed Central.

International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007.
Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA., Int. J. Cancer 139(7), 2016
PMID: 27244487
Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection.
Chuang SC, La Vecchia C, Boffetta P., Cancer Lett. 286(1), 2008
PMID: 19091458

AUTHOR UNKNOWN, 2016
Body Fatness and Cancer--Viewpoint of the IARC Working Group.
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K; International Agency for Research on Cancer Handbook Working Group, Colditz G, Anderson AS, Herbert RA, Kaaks R, Thompson HJ, Baker JL, Breda J, Byers T, Cleary MP, Di Cesare M, Gapstur SM, Gunter M, Hursting SD, Leitzmann M, Ligibel J, Renehan A, Romieu I, Shimokawa I, Ulrich CM, Wade K, Weiderpass E., N. Engl. J. Med. 375(8), 2016
PMID: 27557308

AUTHOR UNKNOWN, 2016

AUTHOR UNKNOWN, 2013
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F., Int. J. Cancer 136(5), 2014
PMID: 25220842
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA., Cancer 122(9), 2016
PMID: 26959385
Attributable causes of liver cancer mortality and incidence in china.
Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, Qiao YL, Boffetta P., Asian Pac. J. Cancer Prev. 14(12), 2013
PMID: 24460283
Etiological and molecular profile of hepatocellular cancer from India.
Asim M, Sarma MP, Kar P., Int. J. Cancer 133(2), 2013
PMID: 23233429
Global burden of cancers attributable to infections in 2012: a synthetic analysis.
Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S., Lancet Glob Health 4(9), 2016
PMID: 27470177
Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.
Makarova-Rusher OV, Altekruse SF, McNeel TS, Ulahannan S, Duffy AG, Graubard BI, Greten TF, McGlynn KA., Cancer 122(11), 2016
PMID: 26998818
World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.
de Martel C, Maucort-Boulch D, Plummer M, Franceschi S., Hepatology 62(4), 2015
PMID: 26146815
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabe E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castaneda-Orjuela C, Catala-Lopez F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Soreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabares-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M., JAMA Oncol 3(4), 2017
PMID: 27918777
Modeling causes of death: an integrated approach using CODEm.
Foreman KJ, Lozano R, Lopez AD, Murray CJ., Popul Health Metr 10(), 2012
PMID: 22226226

AUTHOR UNKNOWN, 2015
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010.
Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, Begum N, Shah R, Karyana M, Kosen S, Farje MR, Moncada G, Dutta A, Sazawal S, Dyer A, Seiler J, Aboyans V, Baker L, Baxter A, Benjamin EJ, Bhalla K, Bin Abdulhak A, Blyth F, Bourne R, Braithwaite T, Brooks P, Brugha TS, Bryan-Hancock C, Buchbinder R, Burney P, Calabria B, Chen H, Chugh SS, Cooley R, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, Davis A, Degenhardt L, Diaz-Torne C, Dorsey ER, Driscoll T, Edmond K, Elbaz A, Ezzati M, Feigin V, Ferri CP, Flaxman AD, Flood L, Fransen M, Fuse K, Gabbe BJ, Gillum RF, Haagsma J, Harrison JE, Havmoeller R, Hay RJ, Hel-Baqui A, Hoek HW, Hoffman H, Hogeland E, Hoy D, Jarvis D, Karthikeyan G, Knowlton LM, Lathlean T, Leasher JL, Lim SS, Lipshultz SE, Lopez AD, Lozano R, Lyons R, Malekzadeh R, Marcenes W, March L, Margolis DJ, McGill N, McGrath J, Mensah GA, Meyer AC, Michaud C, Moran A, Mori R, Murdoch ME, Naldi L, Newton CR, Norman R, Omer SB, Osborne R, Pearce N, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Pourmalek F, Prince M, Rehm JT, Remuzzi G, Richardson K, Room R, Saha S, Sampson U, Sanchez-Riera L, Segui-Gomez M, Shahraz S, Shibuya K, Singh D, Sliwa K, Smith E, Soerjomataram I, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Taylor HR, Tleyjeh IM, van der Werf MJ, Watson WL, Weatherall DJ, Weintraub R, Weisskopf MG, Whiteford H, Wilkinson JD, Woolf AD, Zheng ZJ, Murray CJ, Jonas JB., Lancet 380(9859), 2012
PMID: 23245605

AUTHOR UNKNOWN, 1993
Hepatocellular carcinoma epidemiology.
Bosetti C, Turati F, La Vecchia C., Best Pract Res Clin Gastroenterol 28(5), 2014
PMID: 25260306
International trends in liver cancer incidence rates.
Center MM, Jemal A., Cancer Epidemiol. Biomarkers Prev. 20(11), 2011
PMID: 21921256
The global epidemiology of hepatocellular carcinoma: present and future.
McGlynn KA, London WT., Clin Liver Dis 15(2), 2011
PMID: 21689610
Requirements for global elimination of hepatitis B: a modelling study.
Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, Hallett TB., Lancet Infect Dis 16(12), 2016
PMID: 27638356
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.
Ward JW, Mermin JH., N. Engl. J. Med. 373(27), 2015
PMID: 26575359
Access to hepatitis C medicines.
Edwards DJ, Coppens DG, Prasad TL, Rook LA, Iyer JK., Bull. World Health Organ. 93(11), 2015
PMID: 26549908
Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.
Guirguis J, Chhatwal J, Dasarathy J, Rivas J, McMichael D, Nagy LE, McCullough AJ, Dasarathy S., Alcohol. Clin. Exp. Res. 39(11), 2015
PMID: 26500036

AUTHOR UNKNOWN, 0
Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.
Liu Y, Wu F., Environ. Health Perspect. 118(6), 2010
PMID: 20172840
Global burden of human food-borne trematodiasis: a systematic review and meta-analysis.
Furst T, Keiser J, Utzinger J., Lancet Infect Dis 12(3), 2011
PMID: 22108757
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M., Hepatology 64(1), 2016
PMID: 26707365
Incidence trend of liver cancer: an analysis of 40 years data from Qidong population-based cancer registry
AUTHOR UNKNOWN, 2014
[Mortality and survival analysis of liver cancer in China].
Zheng R, Zuo T, Zeng H, Zhang S, Chen W., Zhonghua Zhong Liu Za Zhi 37(9), 2015
PMID: 26813436
Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.
Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, Lu P, Hsia CC, Wang N, Xu L, Lu L, Huang F, Zhu Y, Lu J, Ni Z, Zhang Q, Wu Y, Liu G, Wu Z, Qu C, Gail MH., Carcinogenesis 34(8), 2013
PMID: 23322152
Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population.
Hao XS, Wang PP, Chen KX, Li Q, He M, Yu SB, Guo ZY, Perruccio A, Rohan T., Eur. J. Cancer Prev. 12(4), 2003
PMID: 12883379
Cancer incidence and cancer control in Mongolia: Results from the National Cancer Registry 2008-12.
Chimed T, Sandagdorj T, Znaor A, Laversanne M, Tseveen B, Genden P, Bray F., Int. J. Cancer 140(2), 2016
PMID: 27716912
The increasing burden of imported chronic hepatitis B--United States, 1974-2008.
Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA., PLoS ONE 6(12), 2011
PMID: 22163270
Is chronic hepatitis B being undertreated in the United States?
Cohen C, Holmberg SD, McMahon BJ, Block JM, Brosgart CL, Gish RG, London WT, Block TM., J. Viral Hepat. 18(6), 2010
PMID: 21143343

AUTHOR UNKNOWN, 2016
Sorafenib in advanced hepatocellular carcinoma.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group, Pallota MG, Zarba JJ, Boyer M, Riordan S, Strickland A, Tebbutt N, Thomson B, Borbath I, De Greve J, Van Laethem JL, Van Steenbergen W, Van Vlierberghe H, Barrios C, Cosme de Oliveira A, Kotzev I, Takov D, Tchernev K, Burak K, Ma M, Metrakos P, Olweny C, Sherman M, Gamargo Garate C, Martinez-Castillo J, Beaugrand M, Bennouna J, Blanc JF, Bronowicki JP, Degos F, Dominguez S, Grange JD, Hillon P, Raoul JL, Seitz JF, Blum H, Buggisch P, Caspary W, Dollinger M, Galle PR, Gerken G, Goke B, Gregor M, Greten T, Haussinger D, Scherubl J, Scheulen M, Schmid R, Spengler U, Wiest R, Zeuzem S, Arvanitakis C, Germanidis G, Katsos I, Figer A, Stemmer S, Amadori D, Bolondi L, Cognetti F, Craxi A, Farinati F, Gridelli C, Martoni A, Mazzaferro V, Porta C, Ricci S, Sangiovanni A, Santoro A, Trevisani F, Cisnero Garza LE, Gane E, O'Donnell A, Leon J, Lozano A, Jassem J, Rydzewska G, Szawlowski A, Tomczak P, Badulescu F, Miron L, Kubyshkin V, Bruix J, Forner A, Bustamante Schneider J, Diago M, Montero Alvarez JL, Pascual S, Ruiz del Arbol L, Sangro B, Sola R, Tabernero J, Muellhaupt B, Roth A, Jeffry Evans TR, Falk S, Meyer T, Reeves H, Ross P, Befeler A, Boyer T, Britten C, Byrne T, Garcia-Tsao G, Gold P, Goldenberg A, Heuman D, Kennedy P, Koch A, Llovet JM, Marrero J, Schilsky M, Schwartz J, Schwartz M., N. Engl. J. Med. 359(4), 2008
PMID: 18650514
Advanced Hepatocellular Cancer: the Current State of Future Research.
Connell LC, Harding JJ, Abou-Alfa GK., Curr Treat Options Oncol 17(8), 2016
PMID: 27344158
The accuracy of liver cancer as the underlying cause of death on death certificates.
Percy C, Ries LG, Van Holten VD., Public Health Rep 105(4), 1990
PMID: 2116637
Improving the public health utility of global cardiovascular mortality data: the rise of ischemic heart disease.
Ahern RM, Lozano R, Naghavi M, Foreman K, Gakidou E, Murray CJ., Popul Health Metr 9(), 2011
PMID: 21406100
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network.
Chang IC, Huang SF, Chen PJ, Chen CL, Chen CL, Wu CC, Tsai CC, Lee PH, Chen MF, Lee CM, Yu HC, Lo GH, Yeh CT, Hong CC, Eng HL, Wang J, Tseng HH, Hsiao CH, Wu HD, Yen TC, Liaw YF., Medicine (Baltimore) 95(15), 2016
PMID: 27082566

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 28983565
PubMed | Europe PMC

Suchen in

Google Scholar